vs

Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and PDF SOLUTIONS INC (PDFS). Click either name above to swap in a different company.

PDF SOLUTIONS INC is the larger business by last-quarter revenue ($62.4M vs $37.2M, roughly 1.7× GYRE THERAPEUTICS, INC.). PDF SOLUTIONS INC runs the higher net margin — -0.1% vs -3.7%, a 3.6% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 24.6%). PDF SOLUTIONS INC produced more free cash flow last quarter ($7.5M vs $-5.8M). Over the past eight quarters, PDF SOLUTIONS INC's revenue compounded faster (22.9% CAGR vs 17.0%).

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

PDF Solutions, Inc. is an American multinational software and engineering services company based in Santa Clara, California. The company is listed in the Nasdaq stock exchange under the ticker symbol PDFS.

GYRE vs PDFS — Head-to-Head

Bigger by revenue
PDFS
PDFS
1.7× larger
PDFS
$62.4M
$37.2M
GYRE
Growing faster (revenue YoY)
GYRE
GYRE
+8.9% gap
GYRE
33.4%
24.6%
PDFS
Higher net margin
PDFS
PDFS
3.6% more per $
PDFS
-0.1%
-3.7%
GYRE
More free cash flow
PDFS
PDFS
$13.3M more FCF
PDFS
$7.5M
$-5.8M
GYRE
Faster 2-yr revenue CAGR
PDFS
PDFS
Annualised
PDFS
22.9%
17.0%
GYRE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GYRE
GYRE
PDFS
PDFS
Revenue
$37.2M
$62.4M
Net Profit
$-1.4M
$-48.0K
Gross Margin
95.3%
72.9%
Operating Margin
0.3%
5.5%
Net Margin
-3.7%
-0.1%
Revenue YoY
33.4%
24.6%
Net Profit YoY
-340.1%
-108.9%
EPS (diluted)
$-0.01
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GYRE
GYRE
PDFS
PDFS
Q4 25
$37.2M
$62.4M
Q3 25
$30.6M
$57.1M
Q2 25
$26.8M
$51.7M
Q1 25
$22.1M
$47.8M
Q4 24
$27.9M
$50.1M
Q3 24
$25.5M
$46.4M
Q2 24
$25.2M
$41.7M
Q1 24
$27.2M
$41.3M
Net Profit
GYRE
GYRE
PDFS
PDFS
Q4 25
$-1.4M
$-48.0K
Q3 25
$5.9M
$1.3M
Q2 25
$1.6M
$1.1M
Q1 25
$3.7M
$-3.0M
Q4 24
$569.0K
$539.0K
Q3 24
$2.9M
$2.2M
Q2 24
$4.5M
$1.7M
Q1 24
$9.9M
$-393.0K
Gross Margin
GYRE
GYRE
PDFS
PDFS
Q4 25
95.3%
72.9%
Q3 25
94.7%
72.3%
Q2 25
95.7%
71.2%
Q1 25
95.9%
72.9%
Q4 24
95.8%
68.3%
Q3 24
96.2%
73.1%
Q2 24
96.9%
70.6%
Q1 24
96.4%
67.3%
Operating Margin
GYRE
GYRE
PDFS
PDFS
Q4 25
0.3%
5.5%
Q3 25
22.7%
8.5%
Q2 25
8.1%
2.2%
Q1 25
10.3%
-7.4%
Q4 24
2.4%
1.0%
Q3 24
16.6%
4.6%
Q2 24
12.7%
0.6%
Q1 24
29.7%
-4.7%
Net Margin
GYRE
GYRE
PDFS
PDFS
Q4 25
-3.7%
-0.1%
Q3 25
19.4%
2.3%
Q2 25
5.9%
2.2%
Q1 25
16.9%
-6.3%
Q4 24
2.0%
1.1%
Q3 24
11.2%
4.8%
Q2 24
18.0%
4.1%
Q1 24
36.6%
-1.0%
EPS (diluted)
GYRE
GYRE
PDFS
PDFS
Q4 25
$-0.01
$0.00
Q3 25
$0.03
$0.03
Q2 25
$0.00
$0.03
Q1 25
$0.00
$-0.08
Q4 24
$0.00
$0.01
Q3 24
$0.01
$0.06
Q2 24
$0.01
$0.04
Q1 24
$0.03
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GYRE
GYRE
PDFS
PDFS
Cash + ST InvestmentsLiquidity on hand
$52.4M
$42.2M
Total DebtLower is stronger
$67.0M
Stockholders' EquityBook value
$106.0M
$271.0M
Total Assets
$166.1M
$418.7M
Debt / EquityLower = less leverage
0.25×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GYRE
GYRE
PDFS
PDFS
Q4 25
$52.4M
$42.2M
Q3 25
$60.0M
$35.9M
Q2 25
$54.4M
$40.4M
Q1 25
$29.9M
$54.1M
Q4 24
$26.7M
$114.9M
Q3 24
$25.1M
$120.2M
Q2 24
$25.1M
$117.9M
Q1 24
$37.4M
$122.9M
Total Debt
GYRE
GYRE
PDFS
PDFS
Q4 25
$67.0M
Q3 25
$67.6M
Q2 25
$68.1M
Q1 25
$68.7M
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
GYRE
GYRE
PDFS
PDFS
Q4 25
$106.0M
$271.0M
Q3 25
$101.9M
$264.4M
Q2 25
$92.0M
$257.5M
Q1 25
$68.1M
$249.0M
Q4 24
$63.3M
$246.0M
Q3 24
$63.2M
$240.5M
Q2 24
$60.4M
$232.2M
Q1 24
$56.6M
$225.4M
Total Assets
GYRE
GYRE
PDFS
PDFS
Q4 25
$166.1M
$418.7M
Q3 25
$159.4M
$406.4M
Q2 25
$152.6M
$391.1M
Q1 25
$129.8M
$390.0M
Q4 24
$125.4M
$315.3M
Q3 24
$125.2M
$307.4M
Q2 24
$120.9M
$298.0M
Q1 24
$122.0M
$286.8M
Debt / Equity
GYRE
GYRE
PDFS
PDFS
Q4 25
0.25×
Q3 25
0.26×
Q2 25
0.26×
Q1 25
0.28×
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GYRE
GYRE
PDFS
PDFS
Operating Cash FlowLast quarter
$-5.6M
$17.3M
Free Cash FlowOCF − Capex
$-5.8M
$7.5M
FCF MarginFCF / Revenue
-15.5%
12.1%
Capex IntensityCapex / Revenue
0.4%
15.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-180.0K
$-8.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GYRE
GYRE
PDFS
PDFS
Q4 25
$-5.6M
$17.3M
Q3 25
$4.7M
$3.3M
Q2 25
$2.1M
$-5.2M
Q1 25
$-129.0K
$8.6M
Q4 24
$-2.8M
$1.6M
Q3 24
$1.7M
$9.3M
Q2 24
$-5.5M
$684.0K
Q1 24
$2.9M
$-1.9M
Free Cash Flow
GYRE
GYRE
PDFS
PDFS
Q4 25
$-5.8M
$7.5M
Q3 25
$4.0M
$-2.9M
Q2 25
$1.8M
$-13.8M
Q1 25
$-251.0K
$535.0K
Q4 24
$-2.8M
$-4.0M
Q3 24
$1.0M
$5.1M
Q2 24
$-6.9M
$-4.6M
Q1 24
$2.7M
$-3.9M
FCF Margin
GYRE
GYRE
PDFS
PDFS
Q4 25
-15.5%
12.1%
Q3 25
13.1%
-5.1%
Q2 25
6.8%
-26.6%
Q1 25
-1.1%
1.1%
Q4 24
-10.1%
-8.0%
Q3 24
4.1%
11.0%
Q2 24
-27.5%
-11.1%
Q1 24
9.8%
-9.4%
Capex Intensity
GYRE
GYRE
PDFS
PDFS
Q4 25
0.4%
15.7%
Q3 25
2.2%
10.8%
Q2 25
1.0%
16.5%
Q1 25
0.6%
17.0%
Q4 24
0.2%
11.3%
Q3 24
2.7%
9.0%
Q2 24
5.8%
12.8%
Q1 24
0.9%
4.9%
Cash Conversion
GYRE
GYRE
PDFS
PDFS
Q4 25
Q3 25
0.79×
2.54×
Q2 25
1.32×
-4.55×
Q1 25
-0.03×
Q4 24
-4.85×
2.98×
Q3 24
0.60×
4.20×
Q2 24
-1.21×
0.40×
Q1 24
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GYRE
GYRE

Segment breakdown not available.

PDFS
PDFS

Volumebased$38.0M61%
Other$24.4M39%

Related Comparisons